Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM in Patients Who Completed PNEUMOSTEM Phase-I Study
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Sponsors Medipost
- 18 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.